On Wednesday, Briefly Bio announced their pre-seed raise of $1.2M with ambition to become Github for Science.
Anyone that has spent time around science has witnessed that the major time spent is in experimental troubleshooting, not execution. This is an immeasurable cost to the industry and a core bottleneck in the implementation of lab automation technologies.
In the past year, Briefly Bio has built a platform to address this salient gridlock employing a wide feature set which is useful for the experimental executors (scientists) as well as their managers and downstream lab automation engineers.
Briefly Bio specifically works to enable better communication and collaboration through consistent, legible protocols for other scientists and data scientists to understand the context of the numbers they’re working with. Uniquely, Briefly Bio allows scientists to build on each other's work and structures protocols specifically for lab automation. The compounding value of this experimental context means that Briefly is ahead of the curve in capturing experimental context data (not just experiment by experiment data).
After spending copious amounts of time in the field of software-enabled biotech, we (at Compound), saw a unique opportunity in Briefly Bio for addressing an underserved problem. Specifically, we had seen many bio software companies addressing data analysis and bioinformatics workflows but little innovation around upstream processes which dictate the quality of downstream data.
We see Briefly Bio being able to build unique network effects around its protocols, sharing, collaborating, and forking, much like Github has. Enforcing protocol standards is relevant not only to scientists in academia and industry but in publishing and lab automation, expanding the potential market size from other bio software companies.
It’s been a pleasure working with the Briefly team as they build in the protocols whitespace and couldn’t be more enthusiastic about the next stage of their journey!